News

Researchers at Oregon Health and Science University compared the cost, health care resource utilization, and adverse events of chimeric antigen receptor T-cell therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma.

Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...

Researchers reviewed the National Cancer Database records of nearly 32,000 men diagnosed with UIR prostate cancer to determine if men treated with brachytherapy had rates of survival comparable with those of men treated with EBRT.

Findings from a recent study suggest that postoperative hemoglobin testing may be safely avoided unless starting hemoglobin is

According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...

A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.

Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.

Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.

Study findings reveal only 33.9% of commercially insured patients with ovarian cancer received germline BRCA testing, despite guideline recommendations.

When compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies may be associated with less health benefits at higher cost, and that the targeted therapies achieve greater benefits at higher cost.